All Blog /
Corporate Development in Biopharma: How to Evaluate Licensing, Acquisition, and Partnership Opportunities
Business Development

Corporate Development in Biopharma: How to Evaluate Licensing, Acquisition, and Partnership Opportunities

Illumination Strategy Group logo

A term sheet lands in your inbox on a Tuesday, and by Friday someone expects an answer. The numbers look large, the logo is familiar and the science team is excited. What the document does not tell you is whether the deal fits your strategy, whether the structure protects you if development slips, or what you are quietly giving up in the rights you are trading. Corporate development is the discipline that answers those questions, and in biopharma it can shape a company's future more than any single trial. This guide explains how to evaluate licensing, acquisition and partnership opportunities in a way that keeps strategy, science and commercial value in the same conversation.

Why Corporate Development Matters More in Today's Market

Deals have become a central route to capital, validation and scale. J.P. Morgan's Q3 2026 biopharma licensing and venture report puts announced R&D licensing value at $221.1 billion so far this year, and notes that year-to-date M&A and IPO totals have already passed 2025. At the same time, venture funding eased to $6.7 billion in the third quarter from $9.9 billion in the second, which means many companies are weighing a partnership against a financing instead of assuming they can have both.

Headline numbers deserve careful reading, though. J.P. Morgan's first-quarter 2026 review found that upfront cash represented only 6 percent of total licensing deal value. The rest depends on milestones that may or may not arrive. That gap between announced value and cash in the bank is exactly why disciplined corporate development matters: a deal can look transformational on a press release and still leave a small company short of runway.

The backdrop is also unforgiving. BIO, Informa Pharma Intelligence and QLS Advisors found that only 7.9 percent of candidates entering Phase I between 2011 and 2020 reached approval. Any deal that depends on a long chain of future milestones should be priced and structured with that attrition in mind.

What Corporate Development Means for a Biopharma Company

In large pharma, corporate development is a dedicated team that scouts assets, models transactions and negotiates deals. In a growing biotech, the same work often falls on the CEO, a chief business officer or a part-time adviser, usually alongside a dozen other jobs. The function covers three connected activities: finding the right opportunities, evaluating them against the company's strategy and then structuring and closing them in a way that creates value.

One point is easy to miss. Corporate development is not only about buying and selling assets. It also covers how a company positions itself to be an attractive partner, and that depends on having a clear development plan, a credible data package and an honest view of what the company needs from a deal. A business development consultant can help build that foundation before a counterparty ever calls, which is often the cheapest time to do it.

Three Routes: Licensing, Acquisition and Partnership

The terms get used loosely, but the three routes solve different problems and carry different risks.

Licensing

Licensing grants rights to develop or commercialise an asset in exchange for upfront payments, milestones and royalties. For a licensor, it brings non-dilutive capital and a partner with commercial reach, but it also gives up control and a share of future value. For a licensee, it is a way to add a pipeline asset without building it from scratch. The critical questions sit in the details: which territories, which indications, which modalities and what happens if the licensee stops investing.

Acquisition

An acquisition transfers the whole asset or company. It offers the clearest exit for founders and investors, and the clearest route to integration for the buyer. It is also the hardest route to evaluate, because the buyer is taking on everything: the science, the people, the liabilities and the plan. Acquirers often discover that the integration challenge is larger than the valuation challenge, so teams that plan for it early tend to protect more of the value they paid for.

Strategic Partnership

Partnerships sit between the two. They can take the form of co-development, co-commercialisation, platform collaborations or option agreements, where one party buys the right to license an asset later. These structures share cost and risk, and they keep the company's options open. They also demand sound governance, because two organisations with different priorities will need clear rules for decision-making, data sharing and what happens when plans diverge.

Understanding Deal Structure Before You Debate Price

Negotiations often fixate on the headline number, yet structure determines who carries which risk. Upfront payments give certainty today. Milestone payments tie value to development, regulatory and sales events and so move risk to the licensor. Royalties provide a share of long-term sales but depend on a product reaching the market. Equity investments, option fees and cost-sharing arrangements each add another layer of trade-offs.

A useful habit is to ask what the deal looks like in three scenarios: the programme succeeds, it stalls, and it fails. A structure that is generous in the first scenario but leaves you exposed in the second and third is not a good deal, however large the total value. Also check the less glamorous clauses, such as termination rights, diligence obligations on the partner, the ownership of data and improvements, and any exclusivity that could block future opportunities.

A Practical Framework for Evaluating an Opportunity

Whatever the deal type, a consistent framework keeps the team from being swept along by enthusiasm. The five questions below work well in practice, and each one should produce an answer that the whole team can defend.

Does It Fit the Company's Strategy?

Start with the plan, not the asset. A deal should advance the next milestone, strengthen a core franchise or open a market the company has already decided matters. If the team has to stretch the strategy to justify the opportunity, that is usually a sign to pause. Opportunistic deals can be valuable, but only when you can explain what you would stop doing to make room for them.

How Strong Is the Science and the Risk Profile?

Evaluate the evidence as a sceptic would. Look at the quality of the data, the mechanism, the competitive landscape and the regulatory path. Given the low base rate of approval, the question is not whether the asset could succeed but how much of its value depends on assumptions that have not been tested yet. Independent scientific and clinical review is worth the cost here, particularly when the asset sits outside the team's core expertise.

What Is the Commercial Case?

This is where many evaluations are thinnest. A sound commercial assessment looks at the patient population, current standard of care, likely competitors by the time of launch, pricing and reimbursement expectations, and the evidence a payer will want to see. It also asks whether the company has, or can build, the capability to reach those customers. A programme with strong science and a weak market can be a poor deal at almost any price.

Do the Financial Terms Hold Up?

Model the deal on a risk-adjusted basis, using realistic probabilities of success at each stage and realistic timelines. Test how the terms affect the runway, the balance sheet and the next financing. For a licensor, consider how much a partner's upfront payment actually changes the cash position. For a licensee or acquirer, test what the company can afford to fund if the programme needs more investment than expected.

Can the Company Actually Execute It?

Signing is the beginning, not the finish. Ask who will manage the alliance, who owns integration, and whether the organisation has the capacity to do this alongside its existing priorities. Many deals underperform because nobody was clearly accountable after the announcement. Naming an owner and an operating plan before signing is one of the simplest ways to protect value.

Common Mistakes in Biopharma Deal-Making

Several patterns recur. Teams anchor on the headline value and neglect the cash profile. They run commercial diligence late, after the data room has already shaped their view. They treat the first term sheet as the deal rather than as one position in a negotiation. And they let urgency substitute for preparation, accepting a compressed timeline because the counterparty set it.

Another frequent mistake is weak internal alignment. When the science team, the finance lead and the board each hold a different view of what the company wants from a deal, the counterparty will notice and use it. Agreeing on priorities, walk-away points and non-negotiables before the first meeting is far more effective than resolving them under pressure.

When a Business Development Consultant Makes Sense

Not every growing biotech needs a full-time corporate development hire, and many cannot afford one. A business development consultant fills the gap by bringing structured evaluation, market knowledge and deal experience for a defined scope. That might be a partnering strategy ahead of a financing, a commercial assessment of an in-licensing target, or support through term sheet negotiation.

The best engagements are specific. The brief should name the decisions to be made, the deliverables expected and the point at which the company will review the results. A consultant who can also coach the internal team leaves behind a stronger capability, so the next opportunity is easier to evaluate than the last.

How Illumination Strategy Supports Biopharma Deal-Making

Illumination Strategy works with life sciences companies on partnering and corporate development, from early positioning through to evaluating and structuring specific opportunities. Our business development service brings commercial judgement into each stage of the process, so deals are assessed against your strategy and not only against the term sheet.

If you are preparing for a partnering conversation, or weighing an opportunity that has already arrived, start with a conversation about what the company needs from a deal. Our team can help you build the evaluation and negotiation plan before the clock starts running, which is usually when it matters most.

Frequently Asked Questions

What is corporate development in biopharma?

Corporate development is the function that identifies, evaluates and executes strategic transactions such as licensing deals, acquisitions, divestitures and partnerships. It connects the company's strategy to the opportunities available in the market and makes sure each deal supports the development plan, the financial position and the long-term value of the business.

What is the difference between corporate development and business development?

The terms overlap and are often used interchangeably. Corporate development tends to focus on larger structural transactions such as acquisitions, mergers and strategic investments, while business development often centres on licensing, partnering and commercial deals. In smaller biotechs, one person or adviser usually covers both.

How do you evaluate a licensing opportunity?

Start with strategic fit, then assess the scientific evidence, the competitive landscape, the commercial case and the financial terms on a risk-adjusted basis. Review the structure in success, stall and failure scenarios, and check the clauses on termination, diligence obligations, data ownership and exclusivity before debating price.

What should you look for in a partnership agreement?

Look for clear governance, defined decision rights, fair cost and risk sharing, and clauses that address what happens if priorities diverge or one party stops investing. The agreement should also address data and intellectual property ownership, reporting duties and a practical route to exit.

Why does upfront payment matter so much in licensing deals?

Upfront payment is the only part of the value that is certain on signing. J.P. Morgan's first-quarter 2026 data showed it made up just 6 percent of total licensing deal value, so most of the announced figure depends on future milestones. For a small company, upfront cash often determines how much runway the deal really adds.

When should a biotech hire a business development consultant?

Typically when a company is preparing for a financing, entering partnering discussions, assessing an in-licensing or acquisition target, or lacking in-house deal experience. A consultant is most useful before key terms are discussed, when they can shape the strategy and the evaluation criteria.

How long does a biopharma deal take to complete?

It varies with the deal type and complexity. A focused licensing agreement can move in a few months, while acquisitions and multi-asset partnerships often take longer because of diligence, regulatory review and negotiation. Preparing the data room, the model and the internal approvals ahead of time shortens the process.

How can a small biotech become a more attractive partner?

Build a clear development plan, a clean and credible data package, a consistent story and a realistic view of the commercial opportunity. Counterparties respond to companies that know what they want from a deal and can explain what they bring, so preparation often matters as much as the asset itself.

Timothy Glennon, Founder and CEO of Illumination Strategy Group
Timothy Glennon
Founder & CEO — Illumination Strategy Group

With nearly 30 years of life sciences leadership experience, Tim Glennon helps founders, executives, and investors navigate critical growth stages through commercialization strategy, market access, and scalable business planning.

Key Takeaways

  • Upfront cash made up only 6 percent of licensing deal value in early 2026, so headline numbers can overstate what a deal really adds.
  • Licensing, acquisition and partnership solve different problems and carry different risks.
  • Judge a deal's structure in success, stall and failure scenarios before debating price.
  • Test every opportunity on strategic fit, science, commercial case, financial terms and ability to execute.
  • Agree internal priorities and walk-away points before the first negotiation.

Senior Commercial Perspectives, In Your Inbox

Get ISG’s perspectives on life sciences commercial strategy — capital formation, launch, business development, and the leadership decisions that define enterprise value.

More Insights

See how we’ve helped organizations achieve measurable commercialization success across industries.

Executives shaking hands to close a pharma distribution partnership in a meeting room
Business Development

Choosing pharma distributors shapes your launch. Use this guide to compare partners on coverage, compliance, cold chain and deal terms before you sign.

Life sciences leadership team reviewing data around a table during a business transformation planning session
Business Development

Business transformation consulting helps life sciences teams reset commercial strategy after a trial result or funding gap. See the steps that work.

Illumination Strategy Group logo
Business Development

How life sciences companies can use business growth consulting to assess markets, rivals and resources before investing. Read Illumination Strategy's guide.

Illumination Strategy Group logo
Business Development

Learn how corporate development teams evaluate biopharma licensing, acquisitions and partnerships, from deal structure to commercial fit. Read the guide.